Chengxin Ma1, Rui Feng1, Hong Chen2, N U Farrukh Hameed1, Abudumijit Aibaidula1, Yanyan Song3, Jinsong Wu4. 1. Glioma Surgery Division, Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. 2. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China. 3. Department of Biostatistics, Medical School of Shanghai Jiaotong University, Shanghai, China. 4. Glioma Surgery Division, Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: wjsongc@126.com.
Abstract
BACKGROUND: Anaplastic pleomorphic xanthoastrocytoma (PXA) was added to grade III glial tumors as a distinct entity in the 2016 World Health Organization (WHO) classification of tumors of the central nervous system. We retrospectively reviewed and analyzed 55 pathologically confirmed PXA cases according to the newest WHO classification to better clarify the clinical, molecular, and prognostic features of this rare neoplasm. METHODS: In total, 55 pathologically confirmed PXA cases according to the newest WHO classification were retrospectively reviewed and analyzed. After sequencing for BRAF, TERT, IDH1/2, and H3F3A, survival analysis was performed to determine the factors affecting survival. RESULTS: The patients with BRAF V600E mutations were generally younger than those without it, although not statistically significant (27.9 ± 15.4 years and 37.1 ± 17.0 years, respectively, P = 0.054). TERT promoter mutation frequency in PXA was lower than in patients with anaplastic PXA although not statistically significant (4.4% and 28.6%, P = 0.083). One instance of PXA with IDH2 mutation, and no IDH1 and H3F3A mutations were found. In terms of prognosis, patients with anaplastic PXA had shorter overall survival and progression-free survival compared with patients with PXA. The subgroup with gross total resection had a longer median OS (not reached vs. 60.0 months, P = 0.0221) and PFS (not reached vs. 60.0 months, P = 0.0232) compared with patients with PXA with subtotal resection. CONCLUSIONS: The identification of BRAF V600E, TERT, and IDH2 mutations in PXA expands our molecular understanding of PXA. Patients with PXA with gross total resection achieve good outcomes.
BACKGROUND: Anaplastic pleomorphic xanthoastrocytoma (PXA) was added to grade III glial tumors as a distinct entity in the 2016 World Health Organization (WHO) classification of tumors of the central nervous system. We retrospectively reviewed and analyzed 55 pathologically confirmed PXA cases according to the newest WHO classification to better clarify the clinical, molecular, and prognostic features of this rare neoplasm. METHODS: In total, 55 pathologically confirmed PXA cases according to the newest WHO classification were retrospectively reviewed and analyzed. After sequencing for BRAF, TERT, IDH1/2, and H3F3A, survival analysis was performed to determine the factors affecting survival. RESULTS: The patients with BRAF V600E mutations were generally younger than those without it, although not statistically significant (27.9 ± 15.4 years and 37.1 ± 17.0 years, respectively, P = 0.054). TERT promoter mutation frequency in PXA was lower than in patients with anaplastic PXA although not statistically significant (4.4% and 28.6%, P = 0.083). One instance of PXA with IDH2 mutation, and no IDH1 and H3F3A mutations were found. In terms of prognosis, patients with anaplastic PXA had shorter overall survival and progression-free survival compared with patients with PXA. The subgroup with gross total resection had a longer median OS (not reached vs. 60.0 months, P = 0.0221) and PFS (not reached vs. 60.0 months, P = 0.0232) compared with patients with PXA with subtotal resection. CONCLUSIONS: The identification of BRAF V600E, TERT, and IDH2 mutations in PXA expands our molecular understanding of PXA. Patients with PXA with gross total resection achieve good outcomes.
Authors: Antonio Dono; Victor Lopez-Rivera; Ankush Chandra; Cole T Lewis; Rania Abdelkhaleq; Sunil A Sheth; Leomar Y Ballester; Yoshua Esquenazi Journal: Neurooncol Pract Date: 2020-11-20
Authors: Joshua A Hanna; Mansour Mathkour; Edna E Gouveia; JonMark Lane; Lauren Boehm; Joseph R Keen; Erin E Biro; Olawale A Sulaiman; Cuong J Bui Journal: Ochsner J Date: 2020
Authors: Beatrice Detti; Silvia Scoccianti; Virginia Maragna; Sara Lucidi; Michele Ganovelli; Maria Ausilia Teriaca; Saverio Caini; Isacco Desideri; Benedetta Agresti; Daniela Greto; Anna Maria Buccoliero; Alessandro Della Puppa; Iacopo Sardi; Lorenzo Livi Journal: Radiol Med Date: 2022-08-11 Impact factor: 6.313